NYLIM
AMRX icon

New York Life Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

New York Life Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-136,028
Closed -$271K – 1208
2022
Q4 		$271K Buy
136,028
+15,329
+13% +$34.4K ﹤0.01% 1137
2022
Q3 		$244K Buy
120,699
+8,867
+8% +$24.9K ﹤0.01% 1152
2022
Q2 		$356K Buy
+111,832
New +$405K ﹤0.01% 1075

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

New York Life Investment Management's AMRX Position: Q1 2023 in Review

New York Life Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2023, closing a stake of 136,028 shares — an estimated $271K sold.

New York Life Investment Management first reported a position in AMRX in Q2 2022 and held it in 3 quarters. The position peaked at $356K in Q2 2022. 144 funds tracked by Wall St. Rank hold AMRX as of Q1 2023.

  • New York Life Investment Management reported no remaining Amneal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 136,028 Amneal Pharmaceuticals shares in Q1 2023, an estimated $271K.
  • New York Life Investment Management first reported a position in Amneal Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Amneal Pharmaceuticals position peaked at $356K in Q2 2022.
  • 144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.